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Reactivation of hepatitis B virus (HBV) infection in patients with
haematologic malignancies receiving cytotoxic or immunosup-
pressive therapy is well documented (Wands et al, 1975; Lau et al,
1989; Pinto et al, 1990; Ohtsu et al, 1991). It is of interest that in
some of those HBsAg carriers who developed hepatitis during
cytotoxic treatment, seroconversion to an HBsAg-negative state
was observed (Scullard et al, 1981; Hoofnagle et al, 1982;
Alexopoulos et al, 1992).
Information of this kind, in HBsAg-positive patients with solid
tumours, treated with cytotoxic chemotherapy, is very limited and
consisted mainly of case reports (Gallbraith et al, 1975; Ohtsu et
al, 1991; Pinto et al, 1990; Alexopoulos et al, 1992). We therefore
decided to undertake a systematic prospective study of the HBV
profile in such patients, with a twofold aim:
1. to evaluate the prevalence of HBV marker positivity in
patients with solid tumours
2. to study the evolution of HBV profile and the behaviour of
HBsAg carrier state during anti-neoplastic chemotherapy.
Our findings have been previously presented, in abstract form, in
the 33nd Annual Meeting of the American Society of Clinical
Oncology (Alexopoulos et al, 1997).
PATIENTS AND METHODS
Prevalence of HBV markers positivity
Patient population
Between 1986 and 1995, 1402 patients with various solid
tumours were admitted to the Department of Medical Oncology at
Evangelismos Hospital. In 1008 of them (72%) serum markers
for HBV infection were determined before any anticancer
chemotherapy was given (Group A).
A total of 920 patients (91%) of Group A received anti-
neoplastic chemotherapy (Group B) and they served as the main
focus in studying the prevalence of marker positivity. The decision
for not giving chemotherapy in the remaining 88 patients was
based solely on the absence of reasonably effective chemotherapy
for their tumour, their performance status and the presence of
specific medical contra-indications. No patient was excluded on
the basis of the liver status.
Methods
Serum markers for HBV infection, including HBsAg, HBeAg,
HBsAb, HBcAb, and HBeAb, were determined using specific
third-generation enzyme-linked immunosorbent assay (ELISA;
Abbott), at the time of initial presentation in all patients (Group A)
and it was repeated before chemotherapy in the 920 patients of
Group B. Positive results were repeated for confirmation. Liver
function tests including SGOT, SGPT, gGT, LDH, alkaline phos-
phatase, bilirubin, phrothrombin time and serum proteins were
also performed at the same time as HBV profile, before the admin-
istration of any treatment.
Evaluation of HBV profile and behaviour of HBsAg
carrier state during anti-neoplastic chemotherapy
Patient population
Among the 920 patients who received chemotherapy, 538 (59%)
patients had HBV markers determined before and after the
completion of their chemotherapy (Group C), while in 391 (43%)
patients HBV markers were serially determined before
chemotherapy, just after chemotherapy and during their follow-up
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There were 50 HBsAg carriers among the 920 patients of Group
B and all of them were systematically screened for HBsAg and
HBsAb status throughout chemotherapy, during their follow-up or
until their death. Finally, in 30 of the 50 (60%) HBsAg carriers, we
had the opportunity to monitor their HBV profile before, in the
middle, just after the completion of chemotherapy and repeatedly
during their follow-up. Both these groups served as the focus in
studying the behaviour of HBsAg carrier status during cancer
chemotherapy.
Methods
Clinical and laboratory monitoring was as follows:
¥ History was taken and clinical examination was performed
before each course of chemotherapy, during treatment and
every 2 months during follow-up.
¥ Serum HBV marker determined before, in the middle, just
after the completion of chemotherapy and during the
follow-up every 2 months, for 1 year.
¥ Liver function tests including SGOT, SGPT, gGT, LDH,
alkaline phosphatase, bilirubin, prothrombin time and
serum proteins were performed before each course of
chemotherapy during treatment, and every 2 months during
follow-up, for 1 year.
Statistics
Chi-square test was used for comparison of findings.
RESULTS
Patients characteristics
Among the 1008 patients tested before any treatment was given
(Group A), 460 (45.6%) were men and 548 (54.4%) women with a
median age of 59 years (17—78) compared with 426 (46.3%)
men and 494 (53.6%) women with a median age of 58 years
(19—78), in the 920 patients who subsequently received anticancer
chemotherapy (Group B). The distribution of the various malig-
nant solid tumours in the two groups (A and B) together with the
prevalence of HbsAg carriers in each type of malignant tumour are
shown in Tables 1 and 2.
Prevalence of HBV marker positivity
The prevalence of HBV markers in each of the four groups (A, B,
C and D) is shown in Table 3. In Group A, a total of 443 patients
(44%) had at least one marker positive, indicating previous expo-
sure to HBV infection. Fifty-four patients (5.3%) were found to be
HBsAg carriers, and 321 patients (32%) were HBsAb-positive. No
patient was found to be HBeAg-positive, while 212 (21%) were
HBeAb-positive. Finally, 405 patients (40%) had HBc antibodies
in their sera, representing 91% of those screened positive for at
least one marker. None of the 443 patients with at least one HBV
marker positive was demonstrating clinical or biochemical
evidence of hepatitis (data not shown).
The pre-chemotherapy prevalence of HBV marker positivity in
Group B was not statistically different from that of Group A (Table
3). More specifically, the prevalence of HBsAg carriers was 5.4%,
and a total of 396 patients (43%) had at least one HBV marker
positive. Of them, 94% were HBcAb-positive. Similarly, pre-
chemotherapy findings concerning the prevalence of HBsAg
carrier state, HBcAb positivity and the presence of at least one
HBV marker positive were not significantly different in Groups C
and D (Table 3). On the contrary, comparison between the four
groups demonstrated a significantly (P < 0.001) lower prevalence
of serum anti-HBe antibodies in Groups C and D and of anti-HBs
antibodies in Group D (Table 3).
Evolution of HBV profile and HBsAg carrier behaviour
during anti-neoplastic chemotherapy
Table 4 summarizes the findings concerning the changes of HBV
profile just after chemotherapy in the 538 patients of Group C. For
each HBV marker, the overall seroconversion rate was calculated
by dividing the absolute number of changes observed in the corre-
sponding marker with the total number of patients screened (Table
4). Among 37 HBsAg carriers, one had lost HBs antigenaemia
after six courses of chemotherapy while no change was observed
in the status of 501 HBsAg-negative patients for an overall sero-
conversion rate of 0.2% for HBsAg marker. On the other hand,
among 151 HBsAb-positive patients, five lost their HBs anti-
bodies after six courses of chemotherapy, while 15 of the
remaining 387 HBsAb-negative patients developed HBs anti-
bodies in their sera. This represents a 3.7% seroconversion rate for
HBsAb marker. The corresponding overall seroconversion rates,
70 CG Alexopoulos et al
British Journal of Cancer (1999) 81(1), 69–74 © 1999 Cancer Research Campaign
Table 1 Distribution of the various types of cancer and prevalence of
HBsAg carrier state in the 1008 patients, screened before any anticancer
treatment was given (Group A)
Type of cancer Men Women Total HbsAg +ve
(%) (%) (%)
Carcinoma of the lung 196 35 231 15 (6.5)
Carcinoma of the breast 1 260 261 8 (3)
Carcinoma of the GI tracta 103 67 170 7 (4.1)
HD and NHL 55 58 113 14 (12.4)
Urothelial cancer 59 27 86 4 (4.7)
Head and neck cancer 10 6 16 2 (12.5)
Cancer of the ovary – 85 85 4 (4.7)
Other cancers 35 11 46 0
Total 460 (45.6) 548 (54.4) 1008 54 (5.36)
aExcluding hepatocellular carcinoma.
Table 2 Distribution of the various types of cancer and prevalence of HbsAg
carrier state in the 920 patients who received anticancer chemotherapy
(Group B)
Type of cancer Men Women Total HbsAg +ve
(%) (%) (%)
Carcinoma of the lung 176 25 201 14 (6.9)
Carcinoma of the breast 1 225 226 6 (2.65)
Carcinoma of the GI tracta 90 59 149 6 (4)
HD and NHL 55 58 113 14 (12.4)
Urothelial cancer 59 27 86 4 (4.7)
Head and neck cancer 10 4 14 2 (14.3)
Cancer of the ovary – 85 85 4 (4.7)
Other cancers 35 11 46 0
Total 426 (46.4) 494 (53.6) 920 50 (5.4)
aExcluding hepatocellular carcinoma.for HBeAb and HBcAb markers, were 2.4% and 4.6% respec-
tively. No change whatsoever was observed in relation to HBeAg
status.
The evolution of HBV profile, in 391 patients in whom HBV
markers were serially determined before, just after chemotherapy
and during follow-up (Group D), is presented in Table 5. Two of 30
HBsAg-positive patients became HBsAg-negative during follow-
up, for an overall change of 6.6%. Among 86 HBsAb-positive
patients, three lost their HBs antibodies after six courses of
chemotherapy and another one during follow-up, for an overall
change of 4.7%. Major changes were also observed in HBeAb
and HBcAb status. Thus, while before chemotherapy 50 patients
screened positive for HBeAb, the corresponding numbers were
53 after six courses and 58 during follow-up for an overall change
of 16%. Likewise, nine patients developed HBc antibodies after
six courses of chemotherapy and another 11 during follow-up, for
an overall change of 13.3% (Table 5). Finally, serum HBV antige-
naemia remained unchanged in 43 of 50 (86%) HBsAg carriers, in
all measurements performed, and none of these patients developed
clinical signs of hepatitis or liver function abnormalities.
Nevertheless, in seven of 50 (14%), a considerable increase in
serum hepatocellular enzymes was observed, during chemotherapy,
with or without clinical signs of hepatitis. Information about
the clinical course, chemotherapeutic regimens and the use of corti-
costeroids in these seven cases is given in Table 6, while
Table 7 summarizes the changes in the serum HbsAg and HbsAb
titres together with liver function abnormalities observed during
anticancer chemotherapy. Six of seven (86%) patients developed
anti-HBs antibodies in their sera with a parallel decrease in the titre
of HbsAg (a more detailed presentation concerning these seven
patients is planned soon).
In 30 of the 50 (60%) HBsAg carriers, monitoring of HBV
profile before, in the middle, just after the completion of
chemotherapy and repeatedly during follow-up gave the results
shown in Table 8. Two of the 30 HBsAg-positive patients (6.6%)
seroconverted to a HBsAg-negative status during their follow-up.
Among 28 HBsAb-negative patients, three (11%) developed HBs
antibodies. None of the 30 HBcAb-positive patients lost serum
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Table 3 Prevalence of HBV markers in 1008 patients tested at presentation (Group A), 920 patients who received chemotherapy (Group B), 538 patients
tested before and after chemotherapy (Group C) and 391 patients with serial marker determination before and after chemotherapy and during follow-up
(Group D). Results of comparisons between the four groups, for each HBV marker, are shown below with asterisks
Patient Patient no. HBs Ag+ Hbe Ag+ HBs Ab+ Hbe Ab+ HBc Ab+ Any +ve
population (%) (%) (%) (%) (%) (%)
Group A 1008 54 (5.3) 0 321 (32) 212 (21) 405 (40) 443 (44)
Group B 920 50 (5.4)a 0 280 (30)a 178 (19)a 374 (41)a 396 (43)a
Group C 538 37 (6.9)a 0 151 (28)a 80 (15)b 195 (36)a 215 (40)a
Group D 391 30 (7.7)a 0 86 (22)b 50 (13)b 150 (40)a 157 (40)a
aStatistically non-significant; bstatistically significant.
Table 4 Changes in HBV profile in 538 patients screened before and just after chemotherapy (Group C)
HBV marker Before chemo After chemo Absolute number Overall
of changes seroconversion ratea
(%)
HBsAg +ve 37 36 1 1 (0.2)
HBsAg –ve 501 501 0
HBsAb +ve 151 146 5 20 (3.7)
HBsAb –ve 387 372 15
HBeAg +ve 0 0 0 None
HBeAg –ve 538 538 0
HBeAb +ve 80 77 3 13 (2.4)
HBeAb –ve 458 448 10
HBcAb +ve 195 195 0 25 (4.6)
HBcAb –ve 343 318 25
aAbsolute number of changes divided by the total number of patients (538) screened.
Table 5 Evolution of HBV profile in 391 patients serially tested before, just after chemotherapy, and during their follow-up (Group D)
HBV marker Before chemotherapy After chemotherapy During follow-up Overall change
%
HBsAg +ve 30 30 28 6.6
HBsAb +ve 86 83 82 4.7
HBeAg +ve 0 0 0 None
HBeAb +ve 50 53 58 16
HBcAb +ve 150 159 170 13.372 CG Alexopoulos et al
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Table 6 Clinical course, type of chemotherapy used and use of prednisone in the seven patients who developed HBV reactivation as a result of antineoplastic
chemotherapy
Patient Chemotherapeutic regimen Resumption of
no. Sex/Age Diagnosisa (time of HBV reactivation) Prednisone Outcome chemotherapy
1 M/48 NHL CTX+VCR+ADRIA+PRD No Complete Yes
(3rd course of chemo) recovery (3 courses)
2 M/77 SCLC CTX+MTX+VCR+VP-16 Yes Complete No
(6th course of chemo) recovery
3 M/48 SCLC CTX+MTX+VCR+ADRIA+VP-16 No Complete No
(4th course of chemo) recovery
4 F/63 NHL CTX+VCR+ADRIA+PRD Yes Complete Yes
(2nd course of chemo) recovery (4 courses)
5 M/53 NHL IFO+VP-16 No Complete Yes
(4th course of chemo) recovery (2 courses)
6 M/67 APUD 5-FU+FA No Complete No
(6th course of chemo) recovery
7 M/62 NHL CTX+VCR+ADRIA+PRD Yes Complete Yes
(3rd course of chemo) recovery (3 courses)
NHL = Non Hodgkin’s lymphoma; SCLC = small-cell lung cancer; APUD = neuroendocrine tumour; CTX = cyclophosphamide; VCR = vincristine;
ADRIA = adriamycin; PRD = prednisone; MTX = methotrexate; VP-16 = vepesid IFO = ifosfamide; 5-FU = fluorouracil; FA = folinic acid.
Table 7 Changes in HBs antigenaemia, titre of serum HBsAb, and liver function tests in the seven HBsAg carriers who developed clinical and/or biochemical
evidence of hepatitis during anticancer chemotherapy
Patient no. Timing HbsAg HBsAb SGOT SGPT gGT Bilirubin LDH PT
Re: chemo
1 Before 3500 –ve 25 25 10 0.4 232 11¢¢/11¢¢
Middle 2200 750 340 550 27 0.8 491 11¢¢/13¢¢
After 1500 900 25 28 12 0.5 277 11¢¢/11¢¢
2 Before 4000 –ve 20 20 9 0.8 320 11¢¢/11¢¢
Middle 4600 –ve 25 28 19 0.6 270 11¢¢/11¢¢
After 2600 800 700 500 117 17 1925 12¢¢/21¢¢
Follow-up –ve 1300 20 15 23 0.4 212 11¢¢/12¢¢
3 Before 4000 –ve 20 20 10 0.65 219 11¢¢/12¢¢
Middle 2800 900 1900 1300 56 12.5 629 12¢¢/20¢¢
After 2500 1000 20 20 19 1.25 323 11¢¢/12¢¢
4 Before 3000 –ve 39 25 12 0.7 361 11¢¢/11¢¢
Middle 1600 700 388 315 27 4.1 384 11¢¢/16¢¢
After 900 800 28 13 11 0.5 170 11¢¢/12¢¢
5 Before 2500 –ve 20 17 9 0.7 150 12¢¢/11¢¢
Middle 1000 –ve 25 20 10 0.8 162 11¢¢/11¢¢
After –ve 1500 140 190 36 2.4 468 11¢¢/17¢¢
Follow-up –ve 1800 18 13 5 1.3 170 12¢¢/12¢¢
6 Before 1800 –ve 26 18 7.7 0.6 232 13¢¢/12¢¢
Middle 1100 –ve 22 20 11 0.5 228 12¢¢/12¢¢
After –ve 1000 120 115 57 0.7 259 13¢¢/11¢¢
Follow-up –ve 1300 20 15 18 0.65 241 12¢¢/11¢¢
7 Before 3100 –ve 22 17 8 0.9 207 12¢¢/11¢¢
Middle 3000 –ve 24 21 12 0.75 205 11¢¢/11¢¢
After 1600 –ve 124 129 10 0.85 220 11¢¢/12¢¢
Follow-up 1500 –ve 14 16 12 0.7 196 11¢¢/11¢¢
Table 8 Monitoring of HBV profile throughout chemotherapy and during follow-up in 30 HBsAg carrier patients
HBV marker Before Middle After Follow-up Overall change
(%)
HBsAg +ve 30 29 28 28 –2 (6.6)
HBsAb +ve 2 3 2 5 +3 (67)
HBsAb –ve 28 27 28 25 –3 (11)
HBcAb +ve 30 29 28 30 None
HBcAb –ve 0 1 2 0 NA
HBeAb +ve 29 29 29 30 +1 (3.5)
HBeAb –ve 1 1 1 0 –1 (100) anti-HBc antibodies as a result of anti-neoplastic chemotherapy,
while the only HBcAb-negative patient developed serum anti-HBc
antibodies during follow-up.
DISCUSSION
Reactivation of HBV infection leading to clinically evident
hepatitis as a result of the administration of antineoplastic
chemotherapy, in HBsAg carriers, has been well known from
several case reports (Bird et al, 1989; Pinto et al, 1990; Ohtsu et al,
1991; Alexopoulos et al, 1992; Nakamura et al, 1996). Wands
et al (1975) surveyed 85 patients with myeloproliferative and
lymphoproliferative diseases who were given antineoplastic
chemotherapy and observed that, after chemotherapy, HBsAg
titres often increased.
Interestingly enough, a systematic evaluation of the incidence of
HBV marker positivity, in a large number of untreated patients
with solid tumours and a prospective study of the changes of
HBV profile, during antineoplastic chemotherapy, has not been
published so far. From this point of view, our findings referring to
1008 of 1402 (72%) patients with various solid tumours admitted
to the Department of Medical Oncology at Evangelismos Hospital,
and to all 920 patients among them who were given antineoplastic
chemotherapy, give quite interesting information concerning the
prevalence of HBV marker positivity among patients with solid
tumours. This information becomes more important considering
the fact that the Department of Medical Oncology gets the over-
whelming majority of its referrals from the Medical and Surgical
Outpatient Departments and the various Inpatient Departments of
medical and surgical specialties of Evangelismos Hospital, the
biggest general hospital in Greece with an inpatient turnover of
34 000 a year. The findings that 443 out of 1008 patients (44%)
had at least one marker of HBV infection positive, provide an esti-
mate of the cumulative incidence of previous exposure to HBV
infection of the Greek cancer patients. An identical prevalence
(43%) was found among the 920 cancer patients, who received
antineoplastic chemotherapy in our Unit.
Even more important, from the point of view of the possibility
of developing reactivation of HBV infection, during chemo-
therapy, was our finding that 50 of these 920 patients (5.4%) were
HBsAg carriers. This prevalence is 9 times higher than that of
Greek potential blood donors as it has been estimated in a recent
multicentre Greek study comprising 542 701 such persons, regis-
tered in the Blood Transfusion Units of the five biggest hospitals
of Athens in the last 5 years (report in the 1st Hellenic Congress of
Sexually Transmittable Diseases). Official data from the Greek
Ministry of Health, concerning 70% of the Blood Transfusion
Services in Greece, estimate the prevalence of HBsAg carrier state
as 0.71%. Nevertheless, this big difference in the prevalence of
HbsAg positivity between cancer patients and potential blood
donors must be interpreted with caution since blood donors are
young and admittedly healthy people most of whom had appar-
ently been self-selected for blood donation knowing their previous
HBV profile. Unfortunately there exists no official information
about the prevalence of HbsAg carrier state among the general
Greek population.
Ohtsu et al (1991), observed a 3.4% HBsAg carrier state
among 262 patients with haematologic malignancies, a preva-
lence not significantly different from the 5.4% observed in our
series although patient population in the two studies is not
absolutely comparable. Patients in Ohtsu￿s study had exclusively
haematological malignancies and the total number of patients
tested was much smaller in his study.
Ngan et al (1995) reported a very high (30%) HBsAg positivity
among 73 consecutive Chinese patients with aggressive non-
Hodgkin￿s lymphomas treated between 1988 and 1995, a threefold
increase compared with the incidence in general Chinese popula-
tion. Again this is a very selected population of patients. Of
interest are also our findings concerning the evolution of HBV
profile after antineoplastic chemotherapy and during follow-up as
there were observed in Group C and Group D of patients. While
none of the HBs- and HBe-negative patients of Group C developed
HBs or HBe antigenaemia during chemotherapy, the overall
change for HBsAb marker at the same period was 3.7%, without
any evidence of intervening HBV infection or biochemical signs
of reactivation of a subclinical hepatitis. The corresponding
overall change for HBcAb marker was 4.6%. During the follow-up
period (Group D), the biggest changes in the HBV profile were
observed in HBeAb and HBcAb markers with overall changes of
16% and 13% respectively.
The evaluation of the behaviour of HBsAg carrier state and
the systematic assessment of liver biochemistry, throughout
chemotherapy, in the 50 HBsAg-positive patients, together with
the findings of monitoring the complete HBV profile before, in the
middle, just after completion of chemotherapy and repeatedly
during the follow-up in 30 (60%) of them, provide, we believe,
valuable information on the possible consequences of anti-
neoplastic chemotherapy and the likelihood of seroconversion in
HBsAg carrier patients with solid tumours. An overall 14% of
HBsAg carriers (seven patients), developed clinical picture and/or
biochemical findings of hepatitis concurrently with the appear-
ance, for the first time, of anti-HBs antibodies in the sera of six of
them (persistently in three patients) and an associated decrease in
their serum HBsAg levels (persistently in four patients). These
findings together with the negative serological results for hepatitis
C and D, in all five cases tested, strongly support the explanation
that the clinical and/or biochemical hepatitis observed in the seven
HbsAg carriers is due to reactivation of HBV infection as a result
of cytotoxic chemotherapy.
On the other hand, our finding that among the 30 HBsAg carriers
only 6.6% converted to a HBsAg-negative state, persisting during
their follow-up, suggests that conversion of HBs antigenaemia as a
result of antineoplastic chemotherapy, is neither a frequent nor
usually a permanent phenomenon.
Wands et al (1975) reported an increase in serum titre of HBsAg
after chemotherapy in all the HBsAg carriers among the 85
patients with haematological malignancies surveyed. Ohtsu et al
(1991) observed that five of six HBsAg carriers with haematolog-
ical malignancies who received chemotherapy containing pred-
nisone, showed a rise in their serum titre of HBsAg. We believe
that the difference between their observations and ours is mainly
due to the fact that all their patients had haematological malignan-
cies for which high doses of prednisone was given. Furthermore,
their findings concern small numbers of patients retroprospec-
tively studied. Our study, involving a significant number of
patients followed up prospectively and serially throughout
chemotherapy and during follow-up, offers, we think, a more real-
istic picture of the consequences of administration of antineo-
plastic chemotherapy in HBsAg carrier patients.
In conclusion, the prevalence of HBsAg carrier state in cancer
patients is considerably high in Greece and very significantly
higher than that of Greek blood donors. It seems that, during
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reactivation of HBV infection. It would, therefore, be advisable to
screen all cancer patients for HbsAg prior to chemotherapy.
Although the findings would probably not affect the decision about
management, it seems prudent to closely follow those patients
screened positive for the possibility of developing severe hepatitis.
Finally, disappearance of HBs antigenaemia following chemo-
therapy induced reactivation of HBV infection is an infrequent and
usually transient phenomenon.
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